Thrombotic microangiopathy associated with malignant arterial hypertension


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Malignant arterial hypertension is a life-threatening condition accompanied by acute renal failure, which in most cases results in irreversible loss of renal function. The morphological substrate of the disease is often thrombotic microangiopathy the mechanism of which in malignant hypertension is not fully understood. The article presents clinical observations of patients with malignant hypertension and renal dysfunction who had renal biopsy-proven thrombotic microangiopathy. The characteristic feature of both observations is the lack of specific hematologic signs of thrombotic microangiopathy syndrome, which creates diagnostic difficulties. Factors attributed to the lack of microangiopathic hemolysis and thrombocytopenia are described. Potential mechanisms of developing thrombotic microangiopathy in malignant hypertension are discussed.

Full Text

Restricted Access

References

  1. Козловская Н.Л., Колина И.Б., Боброва Л.А., Кучиева А.М., Хафизова Е.Ю. Быстропрогрессирующая почечная недостаточность: всегда ли гломерулонефрит? Лечащий врач. 2012; 6: 63-68.
  2. Barbour T., Johnson S., Cohney S., Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol. Dial. Transplant. 2012; 27(7): 2673- 2685. doi: 10.1093/ndt/gfs279.
  3. Besbas N., Karpman D., Landau D., Loirat C., Proesmans W., Remuzzi G., Rizzoni G., Taylor C.M., Van de Kar N., Zimmerhackl L.B.; European Paediatric Research Group for HUS. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 2006; 70(3): 423-431.
  4. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., Daina E., Fenili C., Castelletti F., Sorosina A., Piras R., Donadelli R., Maranta R., van der Meer I., Conway E.M., Zipfel P.F., Goodship T.H., Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 2010; 5(10): 1844-1859. doi: 10.2215/CJN.02210310.
  5. Chang A. Thrombotic microangiopathy and the kidney: A nephropathologist’s perspective. Diagnostic Histopathology. 2013; 19(5): 158-165.
  6. Tsai H.M. Atypical hemolytic uremic syndrome may present as severe hypertension without hemolysis or thrombocytopenia. Austin J. Nephrol. Hypertens. 2016; 3(1): 1055-1058.
  7. Shibagaki Y., Fujita T. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS) / thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other? Hypertens. Res. 2005; 28(1): 89-95.
  8. Ruggenenti P M., Remuzzi G M. Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. Am. J. Kidney Dis. 1996; 27(4): 459-475.
  9. Van Den Born B.J., Honnebier U.P., Koopmans R.P., van Montfrans G.A. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension. 2005; 45(2): 246-251.
  10. Rodriguez-Pinto I., Espinosa G., Cervera R. Catastrophic APS in the context of other thrombotic microangiopathies. Cur. Rheumatol. Rep. 2015; 17(1): 482. doi: 10.1007/s11926-014-0482-z.
  11. Tsai H.M. A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome. Transfus. Med. Rev. 2014; 28(4): 187-197. doi: 10.1016/j.tmrv.2014.08.004.
  12. Козловская Н.Л., Демьянова К.А., Кузнецов Д.В., Кучиева А.М., Боброва Л.А., Столяревич Е.С. «Субклиническая» тромботическая микроангиопатия при атипичном гемолитико-уремическом синдроме: единичный случай или закономерность? Нефрология и диализ. 2014; 2: 280-287.
  13. Akimoto T., Muto S., Ito C., Takahashi H., Takeda S., Ando Y., Kusano E. Clinical features of malignant hypertension with thrombotic microangiopathy. Clin. Exp. Hypertens. 2011; 33(2): 77-83. doi: 10.3109/10641963.2010.503303.
  14. Vaughan C.J., Delanty N. Hypertensive emergencies. Lancet. 2000; 356(9227): 411-417.
  15. Mathew R.O., Nayer A., Asif A. The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. J. Am. Soc. Hypertens. 2016; 10(4): 352-359. doi: 10.1016/j.jash.2015.12.007.
  16. van den Born B.J., van der Hoeven N.V., Groot E., Lenting P.J., Meijers J.C., Levi M., van Montfrans G.A. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension. 2008; 51(4): 862-866. doi: 10.1161/HYPERTENSI0NAHA.107.103127.
  17. Козловская Н.Л., Боброва Л.А., Шкарупо В.В., Варшавский В.А., Мирошниченко Н.Г. Клинико-морфологические особенности поражения почек у больных с генетической формой тромбофилии. Терапевтический архив. 2009; 8: 30-36.
  18. Боброва Л.А., Козловская Н.Л., Шкарупо В.В., Варшавский В.А., Столяревич Е.С. Влияние генетической формы тромбофилии на клинико-морфологические проявления и характер течения хронического гломерулонефрита. Нефрология и диализ. 2010; 1: 25-33.
  19. Koupepidou P., Deltas C., Christofides T. The MTHFR 677TT and 677CT/1298ACgenotypes in Cypriotpatients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int. Angiol. 2005; 24(3): 287-294.
  20. Giovannini L, Donadio C. Fingertips ischemia, nephroangiosclerosis, and focal segmental glomerulosclerosis: is genetic thrombophilia the unique explanation? Case Rep. Med. 2014; 2014: 832592. doi: 10.1155/2014/832592.
  21. Tsai H.M. Does anticomplement therapy have a role in the management of malignant hypertension? J. Clin. Hypertens. 2016; 18(4): 359-360. doi: 10.1111/jch.12664.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies